60 results on '"Eigentler, Thomas"'
Search Results
2. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects
3. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy
4. Scaling the Mountains: RF Coil Concepts for Cardiac MRI at 14 T and 21 T
5. UV-radiation and MC1R germline mutations are risk factors for the development of conventional and spitzoid melanomas in children and adolescents
6. Sustained complete remission in Sézary syndrome using extracorporeal photopheresis: a multicentric case series
7. Which parameters to use in flow cytometry in the diagnosis and follow up of mycosis fungoides and Sézary syndrome: a prospective study
8. Time to next treatment in primary cutaneous B cell lymphoma: experience on 98 patients
9. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
10. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases
11. Nomogram for Predicting Survival after First-Line Anti-Pd-1 Immunotherapy in Unresectable Stage IV Melanoma: A Multicenter International Study
12. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
13. German S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma” – Long version of the update 2023
14. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
15. What causes the death of patients with cutaneous squamous cell carcinoma? A prospective analysis in 1400 patients
16. Dissecting the treatment-naive ecosystem of human melanoma brain metastasis
17. Deux schémas posologiques de l’association nivolumab (NIVO) plus ipilimumab (IPI) dans le mélanome avancé : résultats à 3 ans de l’étude CheckMate 511
18. Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Immunotherapy
19. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition
20. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group
21. Hematological immune related adverse events after treatment with immune checkpoint inhibitors
22. Prognostic Impact of Perineural Invasion in Cutaneous Squamous Cell Carcinoma: Results of a Prospective Study of 1,399 Tumors
23. CT texture analysis compared to Positron Emission Tomography (PET) and mutational status in resected melanoma metastases
24. Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors
25. Melanoma brain metastases – Interdisciplinary management recommendations 2020
26. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
27. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
28. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma
29. Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy
30. Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma
31. Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry
32. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
33. Immune checkpoint blockade therapy
34. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients
35. Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry
36. Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study
37. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
38. Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany
39. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
40. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
41. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
42. CT imaging of bone and bone marrow infiltration in malignant melanoma—Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT
43. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
44. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
45. 443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011
46. Proliferative Activity, Chromosomal Aberrations, and Tumor-Specific Mutations in the Differential Diagnosis between Blue Nevi and Melanoma
47. CHEK2*1100delC and Risk of Malignant Melanoma: Danish and German Studies and Meta-Analysis
48. Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma Registry
49. A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up
50. Melanoma staging: Facts and controversies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.